In 2008, we plan to start four phase II clinical trials on our lead compounds SYN-111, SYN-118, SYN-115 and SYN-117 informed by data from efficient proof-of-concept studies.
Our development program focuses on new approaches to neurological diseases and disorders.
Our portfolio has a number of compounds with multiple potential indications and multiple targets. This is an ideal portfolio for innovative, experimental medicine techniques, including state-of-the-art imaging tools, to establish rapid proof-of-concept through small, smart clinical trials. This will allow us to find in a cost-effective and efficient manner the best indication for each compound and the best compound for each indication.
Please click in the compounds for further information
SYN-111 is a potent, specific, and orally bioavailable sodium channel blocker with proven anti-epileptic and anxiolytic activity in preclinical studies that are highly predictive of clinical activity in man. In recent Phase III clinical studies in more than 1,200 patients with Lennox Gastaut Syndrome (LGS) - a severe form of epilepsy - SYN-111 resulted in a significant reduction in the incidence and severity of seizures. The onset of clinical anti-epileptic activity was rapid. Eisai was granted approval in the EU in January 2007 to market Inovelon (rufinamide) as adjunctive therapy in LGS. 
